ALS, also called motor neurone disease, steadily destroys the nerve cells that control muscles, leading to weakness, loss of speech and swallowing, and breathing problems. Researchers are testing whether stem cells can support and protect surviving motor neurons, for example by releasing growth factors, but they cannot yet replace the lost nerve cells.
AT A GLANCE · ALS
| Evidence level | Unproven / not recommended outside trials |
|---|---|
| Approved stem cell treatment? | No stem cell therapy is approved for ALS by the US FDA or the European EMA; the FDA advisory committee voted against a mesenchymal cell product in 2023. |
| Typical private price | $10,000 – $50,000 (indicative) |
| Recruiting trials | 11 listed on ClinicalTrials.gov (4 October 2026) |
| Last reviewed | October 2026 |
Does stem cell therapy work for ALS?
The largest test so far was a randomised, placebo-controlled phase 3 trial of a patient’s own bone marrow mesenchymal stem cells engineered to release nerve growth factors, given by spinal injection to 189 people. It did not meet its main goal: about 35% of treated patients versus 28% on placebo met the response target, a difference that could easily be chance, and all secondary goals also failed. In September 2023 an FDA advisory committee voted 17 to 1 that the evidence did not show effectiveness, and the company then withdrew its application to plan a further trial.
A phase 3 trial of another mesenchymal cell product also missed its main goal, with only post-hoc hints in slower-progressing patients. Early trials of neural stem cells injected directly into the spinal cord, including cells engineered to make the growth factor GDNF, have mainly shown that the surgery can be done safely and that cells can survive. No cell therapy has been shown to slow ALS in a well-controlled trial.
Is any stem cell treatment approved for ALS?
No stem cell therapy is approved for ALS by the US FDA or the European EMA; the FDA advisory committee voted against a mesenchymal cell product in 2023. South Korea granted a conditional approval to a mesenchymal stem cell product for ALS in the mid-2010s, but its follow-up phase 3 trial did not meet its primary goal. Outside trials, ALS stem cell treatments are unapproved.
What private clinics offer — and how it compares
Clinics market IV or spinal stem cell injections to people with ALS as a way to slow or halt progression, often with time pressure because the disease moves quickly. The best controlled trials have not shown that stem cells slow ALS, and travel and procedures can be physically hard for people with weak breathing or swallowing.
Proven treatments to discuss first
Before paying for an experimental option, make sure you have explored the established treatments for ALS with your doctor:
- Care in a specialist multidisciplinary ALS/MND clinic
- Disease-slowing medicines such as riluzole, and edaravone where available
- Gene-targeted antisense therapy for people with SOD1-related ALS (FDA-approved 2023)
- Breathing support, including non-invasive ventilation
- Nutrition support, including a feeding tube when swallowing becomes unsafe
- Speech therapy and communication aids, physiotherapy and occupational therapy
How much does stem cell therapy for ALS cost?
Private clinics typically quote $10,000 to $50,000. There is little systematic reporting of ALS-specific clinic prices; general reporting on unapproved stem cell clinics describes charges from several thousand to tens of thousands of dollars per treatment course, before travel. These figures are approximate. Compare prices by country in our cost guide and location guides, and check insurance coverage.
Risks and side effects
- Complications from repeated lumbar punctures or spinal surgery, including headache, infection and nerve damage
- Breathing difficulties or aspiration during sedation in people with weak respiratory muscles
- Infection or contamination from poorly regulated cell products
- Costly travel and procedures that use up limited time and energy
- Being excluded from legitimate clinical trials after receiving unapproved treatments
Recruiting clinical trials for als
On 4 October 2026, ClinicalTrials.gov listed 11 recruiting or soon-to-recruit stem cell studies for this condition, 3 with sites in the United States. Here are up to eight, latest-stage first:
| Study | Phase | Locations | Status |
|---|---|---|---|
| RAPA-501 Therapy for ALS | Phase 2/Phase 3 | United States | Recruiting |
| Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS) | Phase 2 | Italy | Recruiting |
| Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS | Phase 1/Phase 2 | China | Recruiting |
| The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis | Phase 1 | China | Recruiting |
| Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases | N/A | Israel | Recruiting |
| Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells | N/A | Israel | Recruiting |
| Neurologic Stem Cell Treatment Study | N/A | United Arab Emirates, United States | Recruiting |
| Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) | N/A | China | Recruiting |
See all matching studies on ClinicalTrials.gov. A listing is not an endorsement: registration does not mean a study is safe or effective, and genuine trials rarely charge you for the experimental treatment. Ask the study team about costs, placebo groups and follow-up before you enrol. See our clinical trials hub.
Questions to ask before you agree to treatment
- How do your results compare with the 2023 phase 3 trial that found no clear benefit over placebo?
- Is this a registered trial, and will joining it stop me from entering other ALS trials?
- How will you manage my breathing and swallowing during sedation or spinal injections?
- What objective measures, such as the ALSFRS-R score and breathing tests, do you track, and are they published?

Before You Pay: The Stem Cell Clinic Checklist
- 20 questions every legitimate clinic should answer in writing
- A red-flag scorecard to spot unregulated marketing
- Realistic 2026 cost ranges: US, Mexico, Panama & Europe
- How to find a registered clinical trial
Red flags to watch for
- Claims that stem cells can stop, reverse or ‘cure’ ALS
- Pressure to pay quickly because ‘time is running out’
- No plan to share records or coordinate with your ALS specialist team
Stem cell therapy for ALS: FAQs
Does stem cell therapy work for ALS?
Not so far. The largest placebo-controlled trial of a mesenchymal stem cell treatment, in 189 people, did not show a clear benefit, and early neural stem cell trials have mainly tested safety. Research continues, but there is no proven stem cell treatment for ALS.
Is stem cell therapy FDA approved for ALS?
No. In September 2023 an FDA advisory committee voted 17 to 1 that a mesenchymal stem cell product had not been shown to work, and the application was withdrawn. No stem cell therapy is FDA-approved for ALS.
How much does stem cell therapy for ALS cost?
Unapproved clinics typically charge several thousand to tens of thousands of dollars per course, plus travel. Insurance does not cover it, and repeat treatments are often recommended.
Should I join an ALS stem cell clinical trial?
A well-run, registered trial is the safest way to try an experimental cell therapy, because it has safety monitoring and independent oversight. Ask your ALS specialist to help you check ClinicalTrials.gov and judge whether a trial fits your situation.
Is stem cell therapy for ALS covered by insurance?
No, because it is unapproved. Care in a multidisciplinary ALS clinic, approved medicines, breathing support and equipment are the parts usually covered.
Related guides
- Stem cell therapy for autism
- Stem cell therapy for spinal cord injury
- Stem cell therapy for multiple sclerosis
- Stem cell therapy for stroke
- All conditions · Types of stem cell treatment · Clinical trials hub
Sources
- FDA panel concludes that ALS stem cell therapy lacks evidence (PET / BioNews)
- Testimony before the FDA Cellular, Tissue, and Gene Therapy Advisory Committee (Public Citizen)
- FDA panel rejects experimental stem cell therapy for ALS (Medscape)
- Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy (PMC review)
- FDA: Important patient and consumer information about regenerative medicine therapies
- Unproven stem cell interventions: a global public health problem requiring global deliberation (PMC)
Last reviewed October 2026. For general information only — not medical advice. We do not endorse any clinic or product. Always consult a qualified, licensed healthcare professional. See our medical disclaimer and editorial policy.